Endocrine Today’s top 5 articles posted in June

Endocrine Today has compiled a list of the 5 most popular articles posted in June.

Lifestyle advice alone fails to reduce type 2 diabetes risk

Among Norwegian adults at high risk for developing type 2 diabetes, twice-yearly group sessions designed to teach lifestyle modifications did not decrease risk over 2 years. Read more

In new era of diabetes tech, advancements poised to change management for type 1 and type 2

The Endocrine Today June issue cover story tackles diabetes technology. In the past 2 years, the FDA has approved several new developments in diabetes technology, including smaller, more accurate continuous glucose monitors, more user-friendly insulin pumps, and new diabetes apps, algorithms and cloud technology.

“This is an exciting time for people with diabetes because the whole concept of technology is to give people the tools that they can use to improve outcomes,” Martin J. Abrahamson, MB, ChB, from Harvard Medical School and Beth Israel Deaconess Medical Center, told Endocrine Today. Read more

OBSERVE-4D: No amputation risk with canagliflozin in type 2 diabetes

Adults with type 2 diabetes with and without established cardiovascular disease treated with the SGLT2 inhibitor canagliflozin (Invokana, Janssen) did not have an increased risk for below-the-knee amputation compared with patients assigned similar SGLT2 inhibitors or other antidiabetes therapies, according to new data presented at the American Diabetes Association Scientific Sessions. Read more

Long-term testosterone therapy may prompt type 2 diabetes remission in men

Among men with hypogonadism including in a urology registry, long-term treatment with testosterone may lead to remission of type 2 diabetes, according to a speaker at the American Diabetes Association Scientific Sessions. Read more

CMS: Medicare to cover smartphone apps used with CGM

Medicare will soon cover smartphone apps used in conjunction with approved continuous glucose monitors for people with diabetes, according to a statement released by CMS. The rule change follows a push from lawmakers, diabetes advocates and stakeholders, who have called for coverage of connected smartphone apps since CMS first announced CGM devices would be categorized as “durable medical equipment” in January 2017. The policy in place currently restricts beneficiaries from using a smartphone app to share data and alerts from their otherwise coverable CGM. Read more